The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr.
MECHANISM OF ACTION
Pomalidomide (Table 1) is an immunomodulatory analogue of thalidomide with a variety of mechanisms of action, including the decrease of the affinity of multiple myeloma cells to bone marrow stromal cells and modulation of the activity of cytokines in the bone marrow. It has similar antiangiogenic activity to thalidomide, which includes the inhibition of TNF-alpha and co-stimulatory activity of T-cells, but pomalidomide also stimulates apoptosis and cytoxic T-cell activity. Pomalidomide inhibits T-cell regulatory proliferation and suppressor function as well. 1 
PHARMACOKINETICS
Absorption of pomalidomide following oral administration is rapid, with a time to maximum concentration (T max ) of 3 hours. The maximum concentration (C max ) following a 2 mg oral dose is 13 ng/mL, and the mean area under the time versus concentration curve (AUC) is 189 ng×h/mL. Pomalidomide has a mean terminal half life (t 1/2 ) of 8.9 hours. Pomalidomide is hydrolyzed in the liver, primarily by CYP3A4 and CYP1A2, with 5-hydroxy pomalidomide and a hydrolyzed glutarimide form as active metabolites. Elimination is primarily (73%) in the urine: 43% as the 5-hydroxy metabolite, 25% as the glutarimide, and 10% unchanged. Fifteen percent is excreted in the feces. 2 
TOXICITIES
Most of the toxicities listed below are presented according to their degree of severity. Higher grades represent more severe toxicities. Although there are several grading systems for cancer chemotherapy toxicities, all are similar. One of the frequently used systems is the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (http:// evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf). Oncologists generally do not adjust doses or change therapy for grade 1 or 2 toxicities but make, or consider making, dosage reductions or therapy changes for grade 3 or 4 toxicities. Incidence values are rounded to the nearest whole percentage unless incidence was less than or equal to 0.5% A. Cardiovascular: Arrhythmia/bradycardia (grade $ 3) 2% 5 Table 2) is an oral tyrosine kinase inhibitor (TKI) with activity against native and mutant forms of BCR-ABL, including the refractory T315I mutant. TKI theoretically obtains its pharmacodynamic effects through the reduction of phosphorylation of CRKL, a surrogate marker for the inhibition of BCR-ABL. The BCR-ABL fusion gene activates chronic myeloid leukemia (CML); ponatinib is specifically a pan-BCR-ABL inhibitor. Ponatinib also inhibits the FLT3/ITD mutant that is prevalent in acute myeloid leukemia. 9
PHARMACOKINETICS
The t 1/2 of ponatinib is dose-dependent. The steady-state t 1/2 is approximately 22 hours following administration of a 30 mg or greater oral dose. It is believed that steady-state concentration (C ss ) is achieved on day 7. The AUC is 2,434 nM•h. The C max is observed between 4 to 6 hours after administration. The C max is 145 nM after a 45 mg oral dose. After repeated administration, ponatinib has an AF of 1.5 to 2. 9 Ponatinib is metabolized in the liver by 3A4, 2C8, 2D6, and 3A5 isoenzymes. Approximately 87% of ponatinib is eliminated via the feces and 5% in the urine . 
TOXICITIES
Most of the toxicities listed below are presented according to their degree of severity. Higher grades represent more severe toxicities. Although there are several grading systems for cancer chemotherapy toxicities, all are similar. One of the frequently used systems is the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (http:// evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf). Oncologists generally do not adjust doses or change therapy for grade 1 or 2 toxicities but make, or consider making, dosage reductions or therapy changes for grade 3 or 4 toxicities. Incidence values are rounded to the nearest whole percentage unless incidence was less than or equal to 0.5%. A. Cardiovascular: Arterial thrombosis (all grades)
